New drug cocktail targets Hard-to-Treat ovarian and uterine cancers
NCT ID NCT06107868
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests an investigational drug called RP-6306 alongside standard chemotherapy (carboplatin and paclitaxel) in 6 women with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find a safe dose and check for side effects. It is a first step to see if this combination might help when other treatments have stopped working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RP-6306 (a PKMYT1 inhibitor) combined with carboplatin and paclitaxel chemotherapy
What this could lead to
If successful, this could lead to a new treatment option for people with recurrent ovarian or uterine cancer that has not responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 6 participants, focused on safety and dosing. It is too soon to know if the combination will work or be safe for broader use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada